The Medicines and Healthcare products Regulatory Agency (MHRA) approved the medication nerandomilast, sold under the brand name Jascayd, on 8 July 2026 for the treatment of adults with Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). The drug, manufactured by Boehringer Ingelheim Limited International GmbH, is designed to regulate the immune system and reduce lung tissue scarring.
How does nerandomilast treat pulmonary fibrosis?
Nerandomilast works by targeting the biological mechanisms that drive lung scarring, or fibrosis. According to the MHRA, the active ingredient helps regulate the patient’s immune system, which in turn reduces tissue scarring on the lungs. As scar tissue builds up in patients with IPF and PPF, breathing becomes increasingly difficult.
IPF and PPF are conditions where the lung tissue becomes scarred over time.
What is the recommended dosage for Jascayd?
Patients should follow the exact instructions provided by their healthcare professional. The MHRA states that the recommended dose for adults is an 18mg tablet taken orally twice daily. Because this is a prescription-only medication, it must be used under clinical supervision to ensure safety and effectiveness.
What side effects should patients monitor?
Clinical data indicates that the most frequent side effects associated with nerandomilast include diarrhoea and weight loss. The MHRA notes that these effects may occur in more than 1 in 10 individuals. Patients experiencing any adverse reactions are advised to consult their doctor, nurse, or pharmacist.
The agency also encourages the public to report any suspected side effects through the Yellow Card scheme. Reports can be submitted via the official website or through the MHRA Yellow Card mobile app available on the Google Play and Apple App stores.
What is the future outlook for fibrosis treatment?
Julian Beach, MHRA Executive Director, Healthcare Quality and Access, stated that the approval of nerandomilast represents the agency’s commitment to ensuring patients can access safe and effective medicines where there is an unmet clinical need. The MHRA maintains that it will continue to monitor the safety and efficacy of the drug post-approval to ensure that the clinical benefits continue to justify the risks.
If you or a loved one are managing a chronic lung condition, keep a symptom diary. Tracking changes in your breathing or side effects from new medications can help your clinical team make more informed decisions during check-ups.
Frequently Asked Questions
Is nerandomilast available for all patients with lung disease?
No. The MHRA approval is specific to adults diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). It is a prescription-only medicine.
Where can I find the full medical details for Jascayd?
The Summary of Product Characteristics and Patient Information leaflets are expected to be available on the MHRA Products website within seven days of the 8 July 2026 approval date.
What should I do if I experience a side effect?
Contact your healthcare provider immediately. Additionally, you should report the reaction to the MHRA via the Yellow Card scheme to help with ongoing safety monitoring.
Are you or a family member living with a chronic lung condition? Share your experiences in the comments below, or subscribe to our newsletter for the latest updates on respiratory health and medical breakthroughs.
